Pamela Lepera, DO
Hematology & Oncology · Greenville, NCNPI 1053304212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,249 and has fallen 82.7% since, to $216 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NC, where the typical reported total is $1,703.
Across 126 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$211
- E.r. Squibb & Sons, L.L.C.$184
- Genentech USA, Inc.$173
- Pfizer$155
- AstraZeneca$133
- Gilead$114
- plus $975 from 28 others
Across 1 payment — averaging $11,050 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$11K
What the payments were for
- Food & beverage$1,87296%
- Education$724%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $211 |
| E.r. Squibb & Sons, L.L.C. | 15 | $184 |
| Genentech USA, Inc. | 14 | $173 |
| Pfizer | 10 | $155 |
| AstraZeneca(2 entities) | 9 | $133 |
| Gilead(2 entities) | 7 | $114 |
| Astellas Pharma US Inc | 4 | $109 |
| Johnson & Johnson | 5 | $88 |
| Novartis | 4 | $86 |
| Bristol Myers Squibb | 4 | $75 |
| Jazz Pharmaceuticals Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $49 |
| Amgen | 3 | $47 |
| Shire North American Group Inc | 3 | $44 |
| Exelixis Inc. | 3 | $39 |
| Sanofi | 2 | $36 |
| Bayer | 2 | $35 |
| Seagen Inc. | 2 | $32 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Kyowa Kirin, Inc. | 2 | $23 |
| Incyte Corporation | 2 | $23 |
| Tempus AI, Inc | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $19 |
| AbbVie | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| BTG International Inc. | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Dova Pharmaceuticals | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| GSK | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
| Secura Bio, Inc. | 1 | $10 |
How this compares
$1,944 in reported general payments places this provider in the 50th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Greenville
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Taewoong ChoiDurham$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.